Financhill
Back

Relmada Therapeutics Quote, Financials, Valuation and Earnings

U.S. Government Report Alert Tuesday

Discover the Secret Loophole
Sell
34

RLMD
Relmada Therapeutics

Last Price:
3.43
Seasonality Move:
-1.84%

7 Day Trial

ALL ACCESS PASS

$ 7

The Mysterious VC Firm Behind Nvidia's Secret Weapon

Details Here!

Relmada Therapeutics Price Quote

$3.43
-0.01 (-1.72%)
(Updated: November 5, 2024 at 5:40 AM ET)

Relmada Therapeutics Key Stats

Sell
34
Relmada Therapeutics (RLMD) is a Sell

Day range:
$3.36 - $3.67
52-week range:
$1.88 - $7.22
Dividend yield:
0%
P/E ratio:
0.00
P/S ratio:
0.00
P/B ratio:
1.69%

Volume:
113.4K
Avg. volume:
121.9K
1-year change:
8.86%
Market cap:
$103.8M
Revenue:
$0
EPS:
$-2.87

How Much Does Relmada Therapeutics Make?

Data Unavailable

Is Relmada Therapeutics Growing As A Company?

Data Unavailable

Relmada Therapeutics Stock Price Performance

What Is Relmada Therapeutics 52-Week High & Low?

Relmada Therapeutics Price To Free Cash Flow

Data Unavailable

Is It Risky To Buy Relmada Therapeutics?

Is Relmada Therapeutics Cash Flow Positive?

  • What Is RLMD Cash Flow From Operations?
    Cash flow from operations (TTM) is -$48.2M
  • What Is Relmada Therapeutics’s Cash Flow From Financing?
    Cash flow from financing (TTM) is $123.3K
  • What Is Relmada Therapeutics’s Cash Flow From Investing?
    Cash flow from investing (TTM) is $35.7M

Relmada Therapeutics Return On Invested Capital

Data Unavailable

Relmada Therapeutics Earnings Date & Stock Price

Relmada Therapeutics Competitors

Relmada Therapeutics Dividend Yield

Relmada Therapeutics Analyst Estimates

YoY Growth Past Surprise
EPS: 0% 0%
Revenue: 0% 0%

Analyst Recommendations

Buy Recommendations: 3
Hold Recommendations: 0
Sell Recommendations: 0
Price Target: 12.50
Upside from Last Price: 263.37%

Major Shareholders

  • How many RLMD shares are owned by institutional investors?
    15.9M RLMD shares are owned by institutional investors
  • How many RLMD shares are owned by insiders?
    1.2M RLMD shares are owned by insiders